{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:48:05Z","timestamp":1792799285769,"version":"4.5.0"},"reference-count":144,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Suez Canal University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trop Med Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The world has made great strides towards beating malaria, although about half of the world population is still exposed to the risk of contracting malaria. Developing an effective malaria vaccine was a huge challenge for medical science. In 2021 the World Health Organization (WHO) approved the first malaria vaccine, RTS,S\/AS01 vaccine (Mosquirix\u2122), for widespread use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main abstract body<\/jats:title>\n                    <jats:p>This review highlights the history of development, and the different approaches and types of malaria vaccines, and the literature to date. It covers the developmental stages of RTS,S\/AS01 and recommends steps for its deployment. The review explores other potential vaccine candidates and their status, and suggests options for their further development. It also recommends future roles for vaccines in eradicating malaria. Questions remain on how RTS,S vaccine will work in widespread use and how it can best be utilized to benefit vulnerable communities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Malaria vaccines have been in development for almost 60\u00a0years. The RTS,S\/AS01 vaccine has now been approved, but cannot be a stand-alone solution. Development should continue on promising candidates such as R21, PfSPZ and\n                      <jats:italic>P.\u00a0vivax<\/jats:italic>\n                      vaccines. Multi-component vaccines may be a useful addition to other malaria control techniques in achieving eradication of malaria.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41182-023-00516-w","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T06:02:22Z","timestamp":1684303342000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["Malaria vaccines: the 60-year journey of hope and final success\u2014lessons learned and future prospects"],"prefix":"10.1186","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4821-285X","authenticated-orcid":false,"given":"Amal A.","family":"El-Moamly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"El-Sweify","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"516_CR1","first-page":"2020","volume-title":"20 years of global progress and challenges","author":"WHO. World malaria report","year":"2020","unstructured":"WHO. World malaria report. 20 years of global progress and challenges. Geneva: World Health Organization; 2020. p. 2020."},{"key":"516_CR2","unstructured":"WHO. Towards a global action plan for healthy lives and well-being for all. Geneva: World Health Organization. 2018."},{"issue":"3","key":"516_CR3","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1080\/21645515.2019.1669415","volume":"16","author":"MB Laurens","year":"2020","unstructured":"Laurens MB. RTS, S\/AS01 vaccine (Mosquirix\u2122): an overview. Hum Vaccin Immunother. 2020;16(3):480\u20139. https:\/\/doi.org\/10.1080\/21645515.2019.1669415.","journal-title":"Hum Vaccin Immunother"},{"key":"516_CR4","unstructured":"WHO. Malaria fact sheet 2021. Geneva: World Health Organization; 2021."},{"key":"516_CR5","unstructured":"WHO. WHO approves first malaria vaccine: why did it take so long? Geneva: World Health Organization. 2021."},{"key":"516_CR6","unstructured":"WHO. WHO recommends groundbreaking malaria vaccine for children at risk. Geneva: World Health Organization. 2021."},{"key":"516_CR7","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/216160a0","volume":"216","author":"RS Nussenzweig","year":"1967","unstructured":"Nussenzweig RS, Vanderberg J, Most H, Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature. 1967;216:160\u20132. https:\/\/doi.org\/10.1038\/216160a0.","journal-title":"Nature"},{"issue":"1579","key":"516_CR8","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1098\/rstb.2011.0091","volume":"366","author":"AV Hill","year":"2011","unstructured":"Hill AV. Vaccines against malaria. Philos Trans R Soc Lond B Biol Sci. 2011;366(1579):2806\u201314. https:\/\/doi.org\/10.1098\/rstb.2011.0091.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"516_CR9","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.immuni.2010.10.008","volume":"33","author":"F Sallusto","year":"2010","unstructured":"Sallusto F, Lanzavecchia A, Araki K, Ahmed R. From vaccines to memory and back. Immunity. 2010;33:451\u201363.","journal-title":"Immunity"},{"issue":"1","key":"516_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S2221-1691(11)60072-5","volume":"1","author":"V Lorenz","year":"2011","unstructured":"Lorenz V, Karanis P. Malaria vaccines: looking back and lessons learnt. Asian Pac J Trop Biomed. 2011;1(1):74\u20138. https:\/\/doi.org\/10.1016\/S2221-1691(11)60072-5.","journal-title":"Asian Pac J Trop Biomed"},{"issue":"1","key":"516_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4161\/hv.6.1.10396","volume":"6","author":"SL Hoffman","year":"2010","unstructured":"Hoffman SL, Billingsley PF, James E, Richman A, Loyevsky M, Li T, et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccine. 2010;6(1):97\u2013106. https:\/\/doi.org\/10.4161\/hv.6.1.10396.","journal-title":"Hum Vaccine"},{"key":"516_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4161\/hv.6.1.10712","volume":"6","author":"RF Anders","year":"2010","unstructured":"Anders RF, Adda CG, Foley M, Norton RS. Recombinant protein vaccines against the asexual blood stages of Plasmodium falciparum. Hum Vaccine. 2010;6:39\u201353. https:\/\/doi.org\/10.4161\/hv.6.1.10712.","journal-title":"Hum Vaccine"},{"issue":"7","key":"516_CR13","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3389\/fimmu.2016.00463","volume":"7","author":"L R\u00e9nia","year":"2016","unstructured":"R\u00e9nia L, Goh YS. Malaria parasites: the great escape. Front Immunol. 2016;7(7):463. https:\/\/doi.org\/10.3389\/fimmu.2016.00463.","journal-title":"Front Immunol"},{"key":"516_CR14","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nature10124","volume":"473","author":"R Rappuoli","year":"2011","unstructured":"Rappuoli R, Aderem A. A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature. 2011;473:463\u20139. https:\/\/doi.org\/10.1038\/nature10124.","journal-title":"Nature"},{"issue":"7","key":"516_CR15","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1182\/blood.V92.7.2527","volume":"92","author":"M Cappadoro","year":"1998","unstructured":"Cappadoro M, Giribaldi G, O\u2019Brien E, Turrini F, Manu F, Ulliers D, et al. Early phagocytosis of glucose-6-phosphate dehydrogenase (G6PD)-deficient erythrocytes parasitized by Plasmodium falciparum may explain malaria protection in G6PD deficiency. Blood. 1998;92(7):2527\u201334.","journal-title":"Blood"},{"issue":"3","key":"516_CR16","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1177\/0049475519846382","volume":"49","author":"AK Pannu","year":"2019","unstructured":"Pannu AK. Malaria today: advances in management and control. Trop Doct. 2019;49(3):160\u20134. https:\/\/doi.org\/10.1177\/0049475519846382.","journal-title":"Trop Doct"},{"key":"516_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41541-020-0196-3","volume":"5","author":"PE Duffy","year":"2020","unstructured":"Duffy PE, Patrick GJ. Malaria vaccines since 2000: progress, priorities, products. NPJ Vaccines. 2020;5:48. https:\/\/doi.org\/10.1038\/s41541-020-0196-3.","journal-title":"NPJ Vaccines"},{"issue":"16","key":"516_CR18","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1111\/febs.14107","volume":"284","author":"K Matuschewski","year":"2017","unstructured":"Matuschewski K. Vaccines against malaria-still a long way to go. FEBS J. 2017;284(16):2560\u20138. https:\/\/doi.org\/10.1111\/febs.14107.","journal-title":"FEBS J"},{"key":"516_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1365-3024.2006.00808.x","volume":"28","author":"K Marsh","year":"2006","unstructured":"Marsh K, Kinyanjui S. Immune effector mechanisms in malaria. Parasite Immunol. 2006;28:51\u201360. https:\/\/doi.org\/10.1111\/j.1365-3024.2006.00808.x.","journal-title":"Parasite Immunol"},{"issue":"4 Suppl","key":"516_CR20","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1038\/nm122516","volume":"11","author":"J Clemens","year":"2005","unstructured":"Clemens J, Jodar L. Introducing new vaccines into developing countries: obstacles, opportunities and complexities. Nat Med. 2005;11(4 Suppl):S12\u20135. https:\/\/doi.org\/10.1038\/nm122516.","journal-title":"Nat Med"},{"key":"516_CR21","unstructured":"Bloom BR, Lambert PH (eds). The vaccine book. 15th edn. Amsterdam: Academic Press; 2003:345\u2013370."},{"issue":"6 Suppl","key":"516_CR22","doi-asserted-by":"publisher","first-page":"289","DOI":"10.4269\/ajtmh.2007.77.289","volume":"77","author":"WR Ballou","year":"2007","unstructured":"Ballou WR, Cahill CP. Two decades of commitment to malaria vaccine development: Glaxo Smith Kline Biologicals. Am J Trop Med Hyg. 2007;77(6 Suppl):289\u201395.","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"516_CR23","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/00000441-197309000-00002","volume":"266","author":"DF Clyde","year":"1973","unstructured":"Clyde DF, Most H, McCarthy VC, Vanderberg JP. Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci. 1973;266(3):169\u201377.","journal-title":"Am J Med Sci"},{"issue":"8","key":"516_CR24","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1086\/339409","volume":"185","author":"SL Hoffman","year":"2002","unstructured":"Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL, et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis. 2002;185(8):1155\u201364.","journal-title":"J Infect Dis"},{"key":"516_CR25","unstructured":"Anonymous. Malaria vaccine is near. New York Times. 1982, 3 August."},{"key":"516_CR26","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S0140-6736(87)90540-X","volume":"1","author":"WR Ballou","year":"1987","unstructured":"Ballou WR, Hoffman SL, Sherwood JA, Hollingdale MR, Neva FA, Hockmeyer WT, et al. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet. 1987;1:1277\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(87)90540-X.","journal-title":"Lancet"},{"issue":"6160","key":"516_CR27","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/332158a0","volume":"332","author":"ME Patarroyo","year":"1988","unstructured":"Patarroyo ME, Amador R, Clavijo P, Moreno A, Guzman F, Romero P, et al. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature. 1988;332(6160):158\u201361. https:\/\/doi.org\/10.1038\/332158a0.","journal-title":"Nature"},{"issue":"4850","key":"516_CR28","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1126\/science.3281260","volume":"240","author":"JC Sadoff","year":"1988","unstructured":"Sadoff JC, Ballou WR, Baron LS, Majarian WR, Brey RN, Hockmeyer WT, et al. Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science. 1988;240(4850):336\u20138. https:\/\/doi.org\/10.1126\/science.3281260.","journal-title":"Science"},{"key":"516_CR29","doi-asserted-by":"publisher","unstructured":"RTS,S Malaria Vaccine Trial Team, Bojang KA, Milligan PJ, Pinder M, et al. Efficacy of RTS,S\/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet. 2001;358(9297):1927\u20131934. doi:https:\/\/doi.org\/10.1016\/S0140-6736(01)06957-4.","DOI":"10.1016\/S0140-6736(01)06957-4"},{"issue":"21","key":"516_CR30","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1056\/NEJMoa1505819","volume":"373","author":"DE Neafsey","year":"2015","unstructured":"Neafsey DE, Juraska M, Bedford T, Benkeser D, Valim C, Griggs A, et al. Genetic diversity and protective efficacy of the RTS, S\/AS01 malaria vaccine. N Engl J Med. 2015;373(21):2025\u201337. https:\/\/doi.org\/10.1056\/NEJMoa1505819.","journal-title":"N Engl J Med"},{"key":"516_CR31","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1146\/annurev.iy.11.040193.003351","volume":"11","author":"EH Nardin","year":"1993","unstructured":"Nardin EH, Nussenzweig RS. T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages. Annu Rev Immunol. 1993;11:687\u2013727. https:\/\/doi.org\/10.1146\/annurev.iy.11.040193.003351.","journal-title":"Annu Rev Immunol"},{"key":"516_CR32","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/1475-2875-8-312","volume":"8","author":"VS Moorthy","year":"2009","unstructured":"Moorthy VS, Ballou WR. Immunological mechanisms underlying protection mediated by RTS, S: a review of the available data. Malar J. 2009;8:312. https:\/\/doi.org\/10.1186\/1475-2875-8-312.","journal-title":"Malar J"},{"key":"516_CR33","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.2147\/RMHP.S219294","volume":"14","author":"N Arora","year":"2021","unstructured":"Arora N, Anbalagan L, Pannu A. Towards Eradication of Malaria: Is the WHO\u2019s RTS, S\/AS01 vaccination effective enough? Risk Manag Healthc Policy. 2021;14:1033\u20139.","journal-title":"Risk Manag Healthc Policy"},{"key":"516_CR34","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMp058217","volume":"353","author":"S Okie","year":"2005","unstructured":"Okie S. Betting on a malaria vaccine. N Engl J Med. 2005;353:1877\u201381.","journal-title":"N Engl J Med"},{"key":"516_CR35","doi-asserted-by":"publisher","unstructured":"Mueller AK, Labaied M, Kappe SH, Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature. 2005;433(7022):164\u2013167. Erratum in: Nature. 2007;446(7131):102. https:\/\/doi.org\/10.1038\/nature03188","DOI":"10.1038\/nature03188"},{"issue":"52","key":"516_CR36","doi-asserted-by":"publisher","first-page":"7452","DOI":"10.1016\/j.vaccine.2015.09.096","volume":"33","author":"TL Richie","year":"2015","unstructured":"Richie TL, Billingsley PF, Sim BK, James ER, Chakravarty S, Epstein JE, et al. Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines. Vaccine. 2015;33(52):7452\u201361. https:\/\/doi.org\/10.1016\/j.vaccine.2015.09.096.","journal-title":"Vaccine"},{"issue":"1","key":"516_CR37","doi-asserted-by":"publisher","first-page":"283","DOI":"10.4269\/ajtmh.20-0435","volume":"104","author":"SA Jongo","year":"2021","unstructured":"Jongo SA, Urbano V, Church LWP, Olotu A, Manock SR, Schindler T, et al. Immunogenicity and protective efficacy of radiation-attenuated and chemo-attenuated PfSPZ vaccines in EquatoGuinean adults. Am J Trop Med Hyg. 2021;104(1):283\u201393. https:\/\/doi.org\/10.4269\/ajtmh.20-0435.","journal-title":"Am J Trop Med Hyg"},{"key":"516_CR38","unstructured":"SmithKlineBeecham Biologicals, Wilde, M. D. Hybrid protein between CS from Plasmodium and HBsAG. (1991)."},{"key":"516_CR39","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1056\/NEJMoa0805832","volume":"361","author":"M Roestenberg","year":"2009","unstructured":"Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med. 2009;361:468\u201377.","journal-title":"N Engl J Med"},{"key":"516_CR40","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/S0140-6736(11)60360-7","volume":"377","author":"M Roestenberg","year":"2011","unstructured":"Roestenberg M, Teirlinck AC, McCall MB, Teelen K, Makamdop KN, Wiersma J, et al. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet. 2011;377:1770\u20136.","journal-title":"Lancet"},{"key":"516_CR41","doi-asserted-by":"publisher","first-page":"7002","DOI":"10.1016\/j.vaccine.2011.07.034","volume":"29","author":"J Friesen","year":"2011","unstructured":"Friesen J, Matuschewski K. Comparative efficacy of pre-erythrocytic whole organism vaccine strategies against the malaria parasite. Vaccine. 2011;29:7002\u20138.","journal-title":"Vaccine"},{"key":"516_CR42","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.chom.2011.05.008","volume":"9","author":"NS Butler","year":"2011","unstructured":"Butler NS, Schmidt NW, Vaughan AM, Aly AS, Kappe SH, Harty JT. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe. 2011;9:451\u201362.","journal-title":"Cell Host Microbe"},{"key":"516_CR43","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.pt.2011.04.003","volume":"27","author":"RF Anders","year":"2011","unstructured":"Anders RF. The case for a subunit vaccine against malaria. Trends Parasitol. 2011;27:330\u20134.","journal-title":"Trends Parasitol"},{"issue":"6152","key":"516_CR44","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1126\/science.1241800","volume":"341","author":"RA Seder","year":"2013","unstructured":"Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013;341(6152):1359\u201365.","journal-title":"Science"},{"key":"516_CR45","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nature21060","volume":"542","author":"B Mordmuller","year":"2017","unstructured":"Mordmuller B, Surat G, Lagler H, Chakravarty S, Ishizuka AS, Lalremruata A, et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature. 2017;542:445\u20139.","journal-title":"Nature"},{"issue":"5","key":"516_CR46","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(17)30104-4","volume":"17","author":"MS Sissoko","year":"2017","unstructured":"Sissoko MS, Healy SA, Katile A, Omaswa F, Zaidi I, Gabriel EE, et al. Safety and efficacy of PfSPZ vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect Dis. 2017;17(5):498\u2013509.","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"516_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006465","volume":"4","author":"ME Polhemus","year":"2009","unstructured":"Polhemus ME, Remich SA, Ogutu BR, Waitumbi JN, Otieno L, Apollo S, et al. Evaluation of RTS, S\/AS02A and RTS, S\/AS01B in adults in a high malaria transmission area. PLoS ONE. 2009;4(7): e6465.","journal-title":"PLoS ONE"},{"issue":"6","key":"516_CR48","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/nm.4110","volume":"22","author":"AS Ishizuka","year":"2016","unstructured":"Ishizuka AS, Lyke KE, DeZure A, Berry AA, Richie TL, Mendoza FH, et al. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med. 2016;22(6):614\u201323.","journal-title":"Nat Med"},{"issue":"10","key":"516_CR49","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1073\/pnas.1615324114","volume":"114","author":"KE Lyke","year":"2017","unstructured":"Lyke KE, Ishizuka AS, Berry AA, Chakravarty S, DeZure A, Enama ME, et al. Attenuated PfSPZ vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proc Natl Acad Sci U S A. 2017;114(10):2711\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"516_CR50","doi-asserted-by":"publisher","first-page":"338","DOI":"10.4269\/ajtmh.17-1014","volume":"99","author":"SA Jongo","year":"2018","unstructured":"Jongo SA, Shekalaghe SA, Church LWP, Ruben AJ, Schindler T, Zenklusen I, et al. Safety, immunogenicity, and protective efficacy against controlled human malaria infection of Plasmodium falciparum sporozoite vaccine in Tanzanian adults. Am J Trop Med Hyg. 2018;99(2):338\u201349.","journal-title":"Am J Trop Med Hyg"},{"issue":"4662","key":"516_CR51","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1126\/science.6204383","volume":"225","author":"JB Dame","year":"1984","unstructured":"Dame JB, Williams JL, McCutchan TF, Weber JL, Wirtz RA, Hockmeyer WT, et al. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science. 1984;225(4662):593\u20139.","journal-title":"Science"},{"issue":"5","key":"516_CR52","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/joim.12223","volume":"275","author":"C Arama","year":"2014","unstructured":"Arama C, Troye-Blomberg M. The path of malaria vaccine development: challenges and perspectives. J Intern Med. 2014;275(5):465\u20136.","journal-title":"J Intern Med"},{"key":"516_CR53","unstructured":"Cohen, J. Vaccine composition against malaria. USA patent. 1996. https:\/\/patents.google.com\/patent\/US20060073171A1\/en. Accessed 30 December 2021."},{"key":"516_CR54","doi-asserted-by":"publisher","unstructured":"RTS,S Malaria Vaccine Evaluation Group, Stoute JA, Slaoui M, Heppner DG, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med. 1997;336(2): 86\u201391. https:\/\/doi.org\/10.1056\/NEJM199701093360202.","DOI":"10.1056\/NEJM199701093360202"},{"issue":"12","key":"516_CR55","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/S1473-3099(15)00239-X","volume":"15","author":"MT White","year":"2015","unstructured":"White MT, Verity R, Griffin JT, Asante KP, Owusu-Agyei S, Greenwood B, et al. Immunogenicity of the RTS, S\/ AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect Dis. 2015;15(12):1450\u20138. https:\/\/doi.org\/10.1016\/S1473-3099(15)00239-X.","journal-title":"Lancet Infect Dis"},{"key":"516_CR56","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/S0140-6736(04)17223-1","volume":"364","author":"PL Alonso","year":"2004","unstructured":"Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, et al. Efficacy of the RTS, S\/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet. 2004;364:1411\u201320.","journal-title":"Lancet"},{"key":"516_CR57","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1056\/NEJMoa1208394","volume":"367","author":"SCTP Rts","year":"2012","unstructured":"Rts SCTP, Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, et al. A phase 3 trial of RTS, S\/AS01 malaria vaccine in African infants. N Engl J Med. 2012;367:2284\u201395.","journal-title":"N Engl J Med"},{"key":"516_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005165","volume":"4","author":"C Guinovart","year":"2009","unstructured":"Guinovart C, Aponte JJ, Sacarlal J, Aide P, Leach A, Bassat Q, et al. Insights into long-lasting protection induced by RTS, S\/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children. PLoS ONE. 2009;4: e5165.","journal-title":"PLoS ONE"},{"key":"516_CR59","doi-asserted-by":"publisher","first-page":"46621","DOI":"10.1038\/srep46621","volume":"7","author":"KA Collins","year":"2017","unstructured":"Collins KA, Snaith R, Cottingham MG, Gilbert SC, Hill AVS. Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. Sci Rep. 2017;7:46621.","journal-title":"Sci Rep"},{"key":"516_CR60","unstructured":"WHO. Scientists share data from first WHO-recommended malaria vaccine. Geneva: World Health Organization; 2021."},{"key":"516_CR61","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1111\/j.1365-2958.2005.05024.x","volume":"59","author":"T Kariu","year":"2006","unstructured":"Kariu T, Ishino T, Yano K, Chinzei Y, Yuda M. CelTOS, a novel malarial protein that mediates transmission to mosquito and vertebrate hosts. Mol Microbiol. 2006;59:1369\u201379.","journal-title":"Mol Microbiol"},{"key":"516_CR62","doi-asserted-by":"publisher","first-page":"5940","DOI":"10.1016\/j.vaccine.2011.06.053","volume":"29","author":"ES Bergmann-Leitner","year":"2011","unstructured":"Bergmann-Leitner ES, Legler PM, Savranskaya T, Ockenhouse CF, Angov E. Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS. Vaccine. 2011;29:5940\u20139.","journal-title":"Vaccine"},{"issue":"Suppl 4","key":"516_CR63","doi-asserted-by":"publisher","first-page":"D13","DOI":"10.1016\/j.vaccine.2015.07.091","volume":"33","author":"SL Hoffman","year":"2015","unstructured":"Hoffman SL, Vekemans J, Richie TL, Duffy PE. The march toward malaria vaccines. Vaccine. 2015;33(Suppl 4):D13\u201323.","journal-title":"Vaccine"},{"issue":"1","key":"516_CR64","doi-asserted-by":"publisher","first-page":"78","DOI":"10.4161\/hv.6.1.10116","volume":"6","author":"AV Hill","year":"2010","unstructured":"Hill AV, Reyes-Sandoval A, O\u2019Hara G, Ewer K, Lawrie A, Goodman A, et al. Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccine. 2010;6(1):78\u201383. https:\/\/doi.org\/10.4161\/hv.6.1.10116.","journal-title":"Hum Vaccine"},{"key":"516_CR65","doi-asserted-by":"publisher","first-page":"54","DOI":"10.4161\/hv.6.1.10463","volume":"6","author":"JT Bruder","year":"2010","unstructured":"Bruder JT, Angov E, Limbach KJ, Richie TL. Molecular vaccines for malaria. Hum Vaccine. 2010;6:54\u201377. https:\/\/doi.org\/10.4161\/hv.6.1.10463.","journal-title":"Hum Vaccine"},{"key":"516_CR66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000998","volume":"6","author":"NW Schmidt","year":"2010","unstructured":"Schmidt NW, Butler NS, Badovinac VP, Harty JT. Extreme CD8 T cell requirements for antimalarial liver-stage immunity following immunization with radiation attenuated sporozoites. PLoS Pathog. 2010;6: e1000998. https:\/\/doi.org\/10.1371\/journal.ppat.1000998.","journal-title":"PLoS Pathog"},{"key":"516_CR67","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1128\/IAI.00740-09","volume":"78","author":"A Reyes-Sandoval","year":"2010","unstructured":"Reyes-Sandoval A, Berthoud T, Alder N, Siani L, Gilbert SC, Nicosia A, et al. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8\u00fe T-cell responses. Infect Immun. 2010;78:145\u201353. https:\/\/doi.org\/10.1128\/IAI.00740-09.","journal-title":"Infect Immun"},{"issue":"2","key":"516_CR68","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.vaccine.2010.10.041","volume":"29","author":"S Capone","year":"2010","unstructured":"Capone S, Reyes-Sandoval A, Naddeo M, Siani L, Ammendola V, Rollier CS, et al. Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. Vaccine. 2010;29(2):256\u201365. https:\/\/doi.org\/10.1016\/j.vaccine.2010.10.041.","journal-title":"Vaccine"},{"issue":"3","key":"516_CR69","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.4049\/jimmunol.1100302","volume":"187","author":"A Reyes-Sandoval","year":"2011","unstructured":"Reyes-Sandoval A, Wyllie DH, Bauza K, Milicic A, Forbes EK, Rollier CS, et al. CD8+ T effector memory cells protect against liver-stage malaria. J Immunol. 2011;187(3):1347\u201357. https:\/\/doi.org\/10.4049\/jimmunol.1100302.","journal-title":"J Immunol"},{"key":"516_CR70","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1128\/CVI.00311-10","volume":"17","author":"K Radosevic","year":"2010","unstructured":"Radosevic K, Rodriguez A, Lemckert AA, van der Meer M, Gillissen G, Warnar C, et al. The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert. Clin Vaccine Immunol. 2010;17:1687\u201394. https:\/\/doi.org\/10.1128\/CVI.00311-10.","journal-title":"Clin Vaccine Immunol"},{"key":"516_CR71","doi-asserted-by":"publisher","first-page":"7092","DOI":"10.1074\/jbc.M106862200","volume":"277","author":"D Rathore","year":"2002","unstructured":"Rathore D, Sacci JB, de la Vega P, McCutchan TF. Binding and invasion of liver cells by Plasmodium falciparum sporozoites. Essential involvement of the amino terminus of circumsporozoite protein. J Biol Chem. 2002;277:7092\u20138.","journal-title":"J Biol Chem"},{"issue":"2","key":"516_CR72","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.vaccine.2008.09.097","volume":"27","author":"SE Bongfen","year":"2009","unstructured":"Bongfen SE, Ntsama PM, Offner S, Smith T, Felger I, Tanner M, et al. The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity. Vaccine. 2009;27(2):328\u201335. https:\/\/doi.org\/10.1016\/j.vaccine.2008.09.097.","journal-title":"Vaccine"},{"key":"516_CR73","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/415694a","volume":"415","author":"TL Richie","year":"2002","unstructured":"Richie TL, Saul A. Progress and challenges for malaria vaccines. Nature. 2002;415:694\u2013701.","journal-title":"Nature"},{"key":"516_CR74","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S0140-6736(03)15267-1","volume":"363","author":"VS Moorthy","year":"2004","unstructured":"Moorthy VS, Good MF, Hill AV. Malaria vaccine developments. Lancet. 2004;363:150\u20136.","journal-title":"Lancet"},{"issue":"11","key":"516_CR75","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1056\/NEJMc1100670","volume":"365","author":"SB Sirima","year":"2011","unstructured":"Sirima SB, Cousens S, Druilhe P. Protection against malaria by MSP3 candidate vaccine. N Engl J Med. 2011;365(11):1062\u20134. https:\/\/doi.org\/10.1056\/NEJMc1100670.","journal-title":"N Engl J Med"},{"issue":"11","key":"516_CR76","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1056\/NEJMoa1008115","volume":"365","author":"MA Thera","year":"2011","unstructured":"Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Ouattara A, Kone AK, et al. A field trial to assess a blood-stage malaria vaccine. N Engl J Med. 2011;365(11):1004\u201313. https:\/\/doi.org\/10.1056\/NEJMoa1008115.","journal-title":"N Engl J Med"},{"key":"516_CR77","doi-asserted-by":"publisher","unstructured":"Payne RO, Milne KH, Elias SC, Edwards NJ, Douglas AD, Brown RE, et al. Demonstration of the blood-stage plasmodium falciparum controlled human malaria infection model to assess efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1\/AS01. J Infect Dis. 2016;213 (11):1743\u20131751. Erratum in: J Infect Dis. 2016;214(6):978. https:\/\/doi.org\/10.1093\/infdis\/jiw039.","DOI":"10.1093\/infdis\/jiw039."},{"key":"516_CR78","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1179\/136485910X12647085215534)","volume":"104","author":"AL Goodman","year":"2010","unstructured":"Goodman AL, Draper SJ. Blood-stage malaria vaccines\u2014recent progress and future challenges. Ann Trop Med Parasitol. 2010;104:189\u2013211. https:\/\/doi.org\/10.1179\/136485910X12647085215534).","journal-title":"Ann Trop Med Parasitol"},{"key":"516_CR79","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1128\/CVI.00082-10","volume":"17","author":"HM El Sahly","year":"2010","unstructured":"El Sahly HM, Patel SM, Atmar RL, Lanford TA, Dube T, Thompson D, et al. Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 Region II malaria vaccine in healthy adults living in an area where malaria is not endemic. Clin Vaccine Immunol. 2010;17:1552\u20139.","journal-title":"Clin Vaccine Immunol"},{"key":"516_CR80","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1016\/j.vaccine.2009.03.014","volume":"27","author":"I Sagara","year":"2009","unstructured":"Sagara I, Dicko A, Ellis RD, Fay MP, Diawara SI, Assadou MH, et al. A randomized controlled phase 2 trial of the blood stage AMA1-C1\/Alhydrogel malaria vaccine in children in Mali. Vaccine. 2009;27:3090\u20138.","journal-title":"Vaccine"},{"key":"516_CR81","doi-asserted-by":"publisher","first-page":"6862","DOI":"10.1016\/j.vaccine.2009.09.011","volume":"27","author":"M Esen","year":"2009","unstructured":"Esen M, Kremsner PG, Schleucher R, G\u00e4ssler M, Imoukhuede EB, Imbault N, et al. Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate. Vaccine. 2009;27:6862\u20138.","journal-title":"Vaccine"},{"key":"516_CR82","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1016\/j.vaccine.2006.06.081","volume":"25","author":"CC Hermsen","year":"2007","unstructured":"Hermsen CC, Verhage DF, Telgt DS, Teelen K, Bousema JT, Roestenberg M, et al. Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial. Vaccine. 2007;25:2930\u201340.","journal-title":"Vaccine"},{"key":"516_CR83","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.parint.2010.05.002","volume":"59","author":"T Horii","year":"2010","unstructured":"Horii T, Shirai H, Jie L, Ishii KJ, Palacpac NQ, Tougan T, et al. Evidences of protection against blood-stage infection of Plasmodium falciparum by the novel protein vaccine SE36. Parasitol Int. 2010;59:380\u20136.","journal-title":"Parasitol Int"},{"key":"516_CR84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064073","volume":"8","author":"NM Palacpac","year":"2013","unstructured":"Palacpac NM, Ntege E, Yeka A, Balikagala B, Suzuki N, Shirai H, et al. Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36. PLoS ONE. 2013;8: e64073.","journal-title":"PLoS ONE"},{"key":"516_CR85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004708","volume":"4","author":"BR Ogutu","year":"2009","unstructured":"Ogutu BR, Apollo OJ, McKinney D, Okoth W, Siangla J, Dubovsky F, et al. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS ONE. 2009;4: e4708.","journal-title":"PLoS ONE"},{"key":"516_CR86","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1086\/339342","volume":"185","author":"B Genton","year":"2002","unstructured":"Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, Rare L, Baisor M, et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1\u20132b trial in Papua New Guinea. J Infect Dis. 2002;185:820\u20137.","journal-title":"J Infect Dis"},{"key":"516_CR87","doi-asserted-by":"publisher","first-page":"8017","DOI":"10.1128\/IAI.73.12.8017-8026.2005","volume":"73","author":"R Audran","year":"2005","unstructured":"Audran R, Cachat M, Lurati F, et al. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect Immun. 2005;73:8017\u201326.","journal-title":"Infect Immun"},{"key":"516_CR88","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/infdis\/jit185","volume":"208","author":"MP Jepsen","year":"2013","unstructured":"Jepsen MP, Jogdand PS, Singh SK, et al. The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas. J Infect Dis. 2013;208:479\u201388.","journal-title":"J Infect Dis"},{"key":"516_CR89","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.vaccine.2012.10.106","volume":"31","author":"LY Bustamante","year":"2013","unstructured":"Bustamante LY, Bartholdson SJ, Crosnier C, Campos MG, Wanaguru M, Nguon C, et al. A full-length recombinant Plasmodium falciparum PfRH5 protein induces inhibitory antibodies that are effective across common PfRH5 genetic variants. Vaccine. 2013;31:373\u20139.","journal-title":"Vaccine"},{"key":"516_CR90","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/ncomms1615","volume":"2","author":"AD Douglas","year":"2011","unstructured":"Douglas AD, Williams AR, Illingworth JJ, et al. The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat Commun. 2011;2:601.","journal-title":"Nat Commun"},{"issue":"5","key":"516_CR91","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1093\/infdis\/jit553","volume":"209","author":"TM Tran","year":"2014","unstructured":"Tran TM, Ongoiba A, Coursen J, Crosnier C, Diouf A, Huang CY, et al. Naturally acquired antibodies specific for Plasmodium falciparum reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from malaria. J Infect Dis. 2014;209(5):789\u201398. https:\/\/doi.org\/10.1093\/infdis\/jit553.","journal-title":"J Infect Dis"},{"key":"516_CR92","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/1475-2875-11-361","volume":"11","author":"E Villasis","year":"2012","unstructured":"Villasis E, Lopez-Perez M, Torres K, Gamboa D, Neyra V, Bendezu J, et al. Anti-Plasmodium falciparum invasion ligand antibodies in a low malaria transmission region, Loreto, Peru. Malar J. 2012;11:361. https:\/\/doi.org\/10.1186\/1475-2875-11-361.","journal-title":"Malar J"},{"key":"516_CR93","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1128\/IAI.00690-13","volume":"81","author":"D Ito","year":"2013","unstructured":"Ito D, Hasegawa T, Miura K, Yamasaki T, Arumugam TU, Thongkukiatkul A, et al. RALP1 is a rhoptry-neck erythrocyte-binding protein of Plasmodium falciparum merozoite and a potential blood-stage vaccine candidate antigen. Infect Immun. 2013;81:4290\u20138.","journal-title":"Infect Immun"},{"key":"516_CR94","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41541-017-0015-7","volume":"2","author":"P Srinivasan","year":"2017","unstructured":"Srinivasan P, Baldeviano GC, Miura K, Diouf A, Ventocilla JA, Leiva KP, et al. A malaria vaccine protects Aotus monkeys against virulent Plasmodium falciparum infection. NPJ Vaccines. 2017;2:14. https:\/\/doi.org\/10.1038\/s41541-017-0015-7.","journal-title":"NPJ Vaccines"},{"issue":"5","key":"516_CR95","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.chom.2019.10.012","volume":"26","author":"SK Tessema","year":"2019","unstructured":"Tessema SK, Nakajima R, Jasinskas A, Monk SL, Lekieffre L, Lin E, et al. Protective immunity against severe malaria in children is associated with a limited repertoire of antibodies to conserved PfEMP1 variants. Cell Host Microbe. 2019;26(5):579-590.e5. https:\/\/doi.org\/10.1016\/j.chom.2019.10.012.","journal-title":"Cell Host Microbe"},{"issue":"7810","key":"516_CR96","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41586-020-2220-1","volume":"582","author":"DK Raj","year":"2020","unstructured":"Raj DK, Das Mohapatra A, Jnawali A, Zuromski J, Jha A, Cham-Kpu G, et al. Anti-PfGARP activates programmed cell death of parasites and reduces severe malaria. Nature. 2020;582(7810):104\u20138. https:\/\/doi.org\/10.1038\/s41586-020-2220-1.","journal-title":"Nature"},{"issue":"6186","key":"516_CR97","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1126\/science.1254417","volume":"344","author":"DK Raj","year":"2014","unstructured":"Raj DK, Nixon CP, Nixon CE, Dvorin JD, DiPetrillo CG, Pond-Tor S, et al. Antibodies to PfSEA-1 block parasite egress from RBCs and protect against malaria infection. Science. 2014;344(6186):871\u20137. https:\/\/doi.org\/10.1126\/science.1254417.","journal-title":"Science"},{"issue":"8","key":"516_CR98","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1172\/JCI66634","volume":"123","author":"MF Good","year":"2013","unstructured":"Good MF, Reiman JM, Rodriguez IB, Ito K, Yanow SK, El-Deeb IM, et al. Cross-species malaria immunity induced by chemically attenuated parasites. J Clin Invest. 2013;123(8):3353\u201362. https:\/\/doi.org\/10.1172\/JCI66634.","journal-title":"J Clin Invest"},{"issue":"8","key":"516_CR99","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1128\/IAI.00157-16","volume":"84","author":"AI Raja","year":"2016","unstructured":"Raja AI, Cai Y, Reiman JM, Groves P, Chakravarty S, McPhun V, et al. Chemically attenuated blood-stage Plasmodium yoelii parasites induce long-lived and strain-transcending protection. Infect Immun. 2016;84(8):2274\u201388. https:\/\/doi.org\/10.1128\/IAI.00157-16.","journal-title":"Infect Immun"},{"issue":"7","key":"516_CR100","doi-asserted-by":"publisher","first-page":"e00062","DOI":"10.1128\/IAI.00062-17","volume":"85","author":"AI Raja","year":"2017","unstructured":"Raja AI, Stanisic DI, Good MF. Chemical attenuation in the development of a whole-organism malaria vaccine. Infect Immun. 2017;85(7):e00062-e117. https:\/\/doi.org\/10.1128\/IAI.00062-17.","journal-title":"Infect Immun"},{"issue":"1","key":"516_CR101","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41541-021-00383-8","volume":"6","author":"SK Singh","year":"2021","unstructured":"Singh SK, Plieskatt J, Chourasia BK, Singh V, Bengtsson KL, Reimer JM, et al. Preclinical development of a Pfs230-Pfs48\/45 chimeric malaria transmission-blocking vaccine. NPJ Vaccines. 2021;6(1):120. https:\/\/doi.org\/10.1038\/s41541-021-00383-8.","journal-title":"NPJ Vaccines"},{"key":"516_CR102","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/263057a0","volume":"263","author":"R Carter","year":"1976","unstructured":"Carter R, Chen DH. Malaria transmission blocked by immunisation with gametes of the malaria parasite. Nature. 1976;263:57\u201360.","journal-title":"Nature"},{"issue":"2","key":"516_CR103","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1084\/jem.177.2.505","volume":"177","author":"PE Duffy","year":"1993","unstructured":"Duffy PE, Pimenta P, Kaslow DC. Pgs28 belongs to a family of epidermal growth factor-like antigens that are targets of malaria transmission-blocking antibodies. J Exp Med. 1993;177(2):505\u201310. https:\/\/doi.org\/10.1084\/jem.177.2.505.","journal-title":"J Exp Med"},{"issue":"1","key":"516_CR104","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1073\/pnas.0609885104","volume":"104","author":"J Kubler-Kielb","year":"2007","unstructured":"Kubler-Kielb J, Majadly F, Wu Y, Narum DL, Guo C, Miller LH, et al. Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25. Proc Natl Acad Sci U S A. 2007;104(1):293\u20138. https:\/\/doi.org\/10.1073\/pnas.0609885104.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"516_CR105","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000265","volume":"5","author":"AK Ghosh","year":"2009","unstructured":"Ghosh AK, Devenport M, Jethwaney D, Kalume DE, Pandey A, Anderson VE, et al. Malaria parasite invasion of the mosquito salivary gland requires interaction between the Plasmodium TRAP and the Anopheles salign proteins. PloS Pathog. 2009;5(1): e1000265.","journal-title":"PloS Pathog"},{"issue":"1","key":"516_CR106","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/imr.12828","volume":"293","author":"RM de Jong","year":"2020","unstructured":"de Jong RM, Tebeje SK, Meerstein-Kessel L, Tadesse FG, Jore MM, Stone W, et al. Immunity against sexual stage Plasmodium falciparum and Plasmodium vivax parasites. Immunol Rev. 2020;293(1):190\u2013215. https:\/\/doi.org\/10.1111\/imr.12828.","journal-title":"Immunol Rev"},{"key":"516_CR107","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1365-3024.1987.tb00511.x","volume":"9","author":"N Kumar","year":"1987","unstructured":"Kumar N. Target antigens of malaria transmission blocking immunity exist as a stable membrane bound complex. Parasite Immunol. 1987;9:321\u201335.","journal-title":"Parasite Immunol"},{"issue":"2","key":"516_CR108","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1017\/S0031182015001341","volume":"143","author":"WJ Stone","year":"2016","unstructured":"Stone WJ, Dantzler KW, Nilsson SK, Drakeley CJ, Marti M, Bousema T, Rijpma SR. Naturally acquired immunity to sexual stage P. falciparum parasites. Parasitology. 2016;143(2):187\u201398. https:\/\/doi.org\/10.1017\/S0031182015001341.","journal-title":"Parasitology"},{"key":"516_CR109","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2174\/1566524011313040002","volume":"13","author":"RR Dinglasan","year":"2013","unstructured":"Dinglasan RR, Armistead JS, Nyland JF, Jiang X, Mao HQ. Single-dose microparticle delivery of a malaria transmission-blocking vaccine elicits a long-lasting functional antibody response. Curr Mol Med. 2013;13:479\u201387.","journal-title":"Curr Mol Med"},{"issue":"9","key":"516_CR110","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003193","volume":"3","author":"MA Penny","year":"2008","unstructured":"Penny MA, Maire N, Studer A, Schapira A, Smith TA. What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines. PLoS ONE. 2008;3(9): e3193.","journal-title":"PLoS ONE"},{"key":"516_CR111","doi-asserted-by":"crossref","unstructured":"Vannice KS,\u00a0Brown GV,\u00a0Akanmori BD,\u00a0Moorthy VS.\u00a0MALVAC 2012 scientific forum: accelerating development of second-generation malaria vaccines.\u00a0Malar J.\u00a02012;\u00a011:\u00a0372,2875\u201311\u2013372.","DOI":"10.1186\/1475-2875-11-372"},{"key":"516_CR112","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1128\/CMR.00074-12","volume":"26","author":"JK Baird","year":"2013","unstructured":"Baird JK. Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin Microbiol Rev. 2013;26:36\u201357.","journal-title":"Clin Microbiol Rev"},{"key":"516_CR113","doi-asserted-by":"publisher","first-page":"397","DOI":"10.4269\/ajtmh.1975.24.397","volume":"24","author":"DF Clyde","year":"1975","unstructured":"Clyde DF. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am J Trop Med Hyg. 1975;24:397\u2013401.","journal-title":"Am J Trop Med Hyg"},{"key":"516_CR114","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005070","volume":"10","author":"M Ar\u00e9valo-Herrera","year":"2016","unstructured":"Ar\u00e9valo-Herrera M, V\u00e1squez-Jim\u00e9nez JM, Lopez-Perez M, Vallejo AF, Amado-Garavito AB, C\u00e9spedes N, et al. Protective efficacy of Plasmodium vivax radiation-attenuated sporozoites in colombian volunteers: a randomized controlled trial. PLoS Negl Trop Dis. 2016;10: e0005070.","journal-title":"PLoS Negl Trop Dis"},{"issue":"24","key":"516_CR115","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1016\/j.vaccine.2004.12.019","volume":"23","author":"EM Malkin","year":"2005","unstructured":"Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura K, et al. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine. 2005;23(24):3131\u20138. https:\/\/doi.org\/10.1016\/j.vaccine.2004.12.019.","journal-title":"Vaccine"},{"issue":"12","key":"516_CR116","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.93683","volume":"2","author":"RO Payne","year":"2017","unstructured":"Payne RO, Silk SE, Elias SC, Milne KH, Rawlinson TA, Llewellyn D, et al. Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies. JCI Insight. 2017;2(12): e93683. https:\/\/doi.org\/10.1172\/jci.insight.93683.","journal-title":"JCI Insight."},{"key":"516_CR117","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41541-018-0083-3","volume":"3","author":"K Singh","year":"2018","unstructured":"Singh K, Mukherjee P, Shakri AR, Singh A, Pandey G, Bakshi M, et al. Malaria vaccine candidate based on Duffy-binding protein elicits strain transcending functional antibodies in a Phase I trial. NPJ Vaccines. 2018;3:48.","journal-title":"NPJ Vaccines"},{"issue":"4815","key":"516_CR118","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1126\/science.3299709","volume":"237","author":"SL Hoffman","year":"1987","unstructured":"Hoffman SL, Oster CN, Plowe CV, Woollett GR, Beier JC, Chulay JD, et al. Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. Science. 1987;237(4815):639\u201342. https:\/\/doi.org\/10.1126\/science.3299709.","journal-title":"Science"},{"issue":"4706","key":"516_CR119","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1126\/science.2409595","volume":"228","author":"F Zavala","year":"1985","unstructured":"Zavala F, Tam JP, Hollingdale MR, Cochrane AH, Quakyi I, Nussenzweig RS, et al. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science. 1985;228(4706):1436\u201340.","journal-title":"Science"},{"issue":"4","key":"516_CR120","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/0882-4010(87)90121-5","volume":"2","author":"JF Young","year":"1987","unstructured":"Young JF, Ballou WR, Hockmeyer WT. Developing a human malaria sporozoite vaccine. Microb Pathog. 1987;2(4):237\u201340.","journal-title":"Microb Pathog"},{"issue":"3","key":"516_CR121","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1086\/600120","volume":"200","author":"KE Kester","year":"2009","unstructured":"Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S\/AS01B and RTS, S\/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis. 2009;200(3):337\u201346.","journal-title":"J Infect Dis"},{"issue":"24","key":"516_CR122","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa0807381","volume":"359","author":"P Bejon","year":"2008","unstructured":"Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, et al. Efficacy of RTS, S\/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med. 2008;359(24):2521\u201332.","journal-title":"N Engl J Med"},{"issue":"10","key":"516_CR123","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025786","volume":"6","author":"A Olotu","year":"2011","unstructured":"Olotu A, Moris P, Mwacharo J, Vekemans J, Kimani D, Janssens M, et al. Circumsporozoite-specific T cell responses in children vaccinated with RTS, S\/AS01E and protection against P. falciparum clinical malaria. PLoS ONE. 2011;6(10): e25786.","journal-title":"PLoS ONE"},{"issue":"10","key":"516_CR124","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007302","volume":"4","author":"S Owusu-Agyei","year":"2009","unstructured":"Owusu-Agyei S, Ansong D, Asante K, Kwarteng Owusu S, Owusu R, WirekoBrobby NA, et al. Randomized controlled trial of RTS, S\/AS02D and RTS, S\/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children. PLoS ONE. 2009;4(10): e7302.","journal-title":"PLoS ONE"},{"issue":"10","key":"516_CR125","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007611","volume":"4","author":"B Lell","year":"2009","unstructured":"Lell B, Agnandji S, von Glasenapp I, Haertle S, Oyakhiromen S, Issifou S, et al. A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS, S malaria vaccine candidates in children in Gabon. PLoS ONE. 2009;4(10): e7611.","journal-title":"PLoS ONE"},{"issue":"7","key":"516_CR126","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1086\/656190","volume":"202","author":"ST Agnandji","year":"2010","unstructured":"Agnandji ST, Asante KP, Lyimo J, Vekemans J, Soulanoudjingar SS, Owusu R, Shomari M, et al. Evaluation of the safety and immunogenicity of the RTS, S\/AS01E malaria candidate vaccine when integrated in the expanded program of immunization. J Infect Dis. 2010;202(7):1076\u201387.","journal-title":"J Infect Dis"},{"issue":"9598","key":"516_CR127","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/S0140-6736(07)61542-6","volume":"370","author":"JJ Aponte","year":"2007","unstructured":"Aponte JJ, Aide P, Renom M, Bassat Q, Sacarlal J, Manaca MN, et al. Safety of the RTS, S\/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I\/IIb trial. Lancet. 2007;370(9598):1543\u201351. https:\/\/doi.org\/10.1016\/S0140-6736(07)61542-6.","journal-title":"Lancet"},{"issue":"24","key":"516_CR128","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1056\/NEJMoa0807773","volume":"359","author":"S Abdulla","year":"2008","unstructured":"Abdulla S, Oberholzer R, Juma O, Kubhoja S, Machera F, Membi C, et al. Safety and immunogenicity of RTS, S\/AS02D malaria vaccine in infants. N Engl J Med. 2008;359(24):2533\u201344. https:\/\/doi.org\/10.1056\/NEJMoa0807773.","journal-title":"N Engl J Med"},{"key":"516_CR129","doi-asserted-by":"publisher","unstructured":"RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386:31\u201345. https:\/\/doi.org\/10.1016\/S0140-6736(15)60721-8.","DOI":"10.1016\/S0140-6736(15"},{"key":"516_CR130","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001685","volume":"11","author":"SCTP Rts","year":"2014","unstructured":"Rts SCTP. Efficacy and safety of the RTS, S\/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 2014;11: e1001685.","journal-title":"PLoS Med"},{"key":"516_CR131","unstructured":"European Medicines Agency. First malaria vaccine receives positive scientific opinion from EMA EMA\/CHMP\/488348\/2015. Press Office, editor. London: EMA; 2015. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2015\/07\/ WC500190447.pdf. Accessed 19 Nov 2021"},{"key":"516_CR132","unstructured":"WHO. Malaria vaccine pilot launched in Malawi 2019. Geneva: World Health Organization; 2019. https:\/\/www.who.int\/news\/item\/23-04-2019-malaria-vaccine-pilot-launched-in-malawi. Accessed 3 Nov 2021"},{"key":"516_CR133","unstructured":"WHO. Q &A on RTS,S malaria vaccine. Geneva: World Health Organization; 2021. https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/q-a-on-rts-s-malaria-vaccine. Accessed 20 Nov 2021."},{"key":"516_CR134","unstructured":"Tables of malaria vaccine projects globally. Geneva: World Health Organization. https:\/\/www.who.int\/immunization\/research\/development\/Rainbow_tables\/en\/. Accessed 30 Dec 2021."},{"key":"516_CR135","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1146\/annurev-micro-090817-062427","volume":"72","author":"MB Laurens","year":"2018","unstructured":"Laurens MB. The promise of a malaria vaccine-are we closer? Annu Rev Microbiol. 2018;72:273\u201392. https:\/\/doi.org\/10.1146\/annurev-micro-090817-062427.","journal-title":"Annu Rev Microbiol"},{"issue":"1","key":"516_CR136","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.chom.2018.06.008","volume":"24","author":"SJ Draper","year":"2018","unstructured":"Draper SJ, Sack BK, King CR, Nielsen CM, Rayner JC, Higgins MK, et al. Malaria vaccines: recent advances and new horizons. Cell Host Microbe. 2018;24(1):43\u201356. https:\/\/doi.org\/10.1016\/j.chom.2018.06.008.","journal-title":"Cell Host Microbe"},{"key":"516_CR137","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1073\/pnas.96.4.1615","volume":"96","author":"YP Shi","year":"1999","unstructured":"Shi YP, Hasnain SE, Sacci JB, Holloway BP, Fujioka H, Kumar N, et al. Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine. Proc Natl Acad Sci USA. 1999;96:1615\u201320.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"516_CR138","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1086\/515331","volume":"177","author":"CF Ockenhouse","year":"1998","unstructured":"Ockenhouse CF, Sun PF, Lanar DE, Wellde BT, Hall BT, Kester K, et al. Phase I\/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis. 1998;177(6):1664\u201373. https:\/\/doi.org\/10.1086\/515331.","journal-title":"J Infect Dis"},{"key":"516_CR139","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1073\/pnas.0307158101","volume":"101","author":"E Prieur","year":"2004","unstructured":"Prieur E, Gilbert SC, Schneider J, Moore AC, Sheu EG, Goonetilleke N, et al. A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses. Proc Natl Acad Sci USA. 2004;101:290\u20135. https:\/\/doi.org\/10.1073\/pnas.0307158101.","journal-title":"Proc Natl Acad Sci USA"},{"key":"516_CR140","doi-asserted-by":"publisher","first-page":"5819","DOI":"10.1128\/IAI.00828-07","volume":"75","author":"CL Hutchings","year":"2007","unstructured":"Hutchings CL, Birkett AJ, Moore AC, Hill AV. Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge. Infect Immun. 2007;75:5819\u201326. https:\/\/doi.org\/10.1128\/IAI.00828-07.","journal-title":"Infect Immun"},{"issue":"10","key":"516_CR141","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.3390\/vaccines9101072","volume":"9","author":"SR Bonam","year":"2021","unstructured":"Bonam SR, R\u00e9nia L, Tadepalli G, Bayry J, Kumar HMS. Plasmodium falciparum malaria vaccines and vaccine adjuvants. Vaccines (Basel). 2021;9(10):1072. https:\/\/doi.org\/10.3390\/vaccines9101072.","journal-title":"Vaccines (Basel)"},{"key":"516_CR142","unstructured":"Malaria Vaccine Technology Roadmap 2006 Executive summary. http:\/\/www.malariavaccine.org\/files\/Malaria_Vaccine_TRM_Final_000.pdf. Accessed 22 Dec 2021."},{"key":"516_CR143","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/192733a0","volume":"192","author":"S Cohen","year":"1961","unstructured":"Cohen S, McGregor IA, Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature. 1961;192:733\u20137. https:\/\/doi.org\/10.1038\/192733a0.","journal-title":"Nature"},{"key":"516_CR144","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1126\/science.406671","volume":"197","author":"WA Siddiqui","year":"1977","unstructured":"Siddiqui WA. An effective immunization of experimental monkeys against a human malaria parasite, Plasmodium falciparum. Science. 1977;197:388\u20139. https:\/\/doi.org\/10.1126\/science.406671.","journal-title":"Science"}],"container-title":["Tropical Medicine and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41182-023-00516-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41182-023-00516-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41182-023-00516-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T07:11:37Z","timestamp":1684307497000},"score":1,"resource":{"primary":{"URL":"https:\/\/tropmedhealth.biomedcentral.com\/articles\/10.1186\/s41182-023-00516-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,17]]},"references-count":144,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["516"],"URL":"https:\/\/doi.org\/10.1186\/s41182-023-00516-w","relation":{},"ISSN":["1349-4147"],"issn-type":[{"value":"1349-4147","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,17]]},"assertion":[{"value":"3 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests as defined by Nature Research, or other interests that might be perceived to influence the results and\/or discussion reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}